ArticleEuropean journal of medical research2025
Hyaluronan-mediated motility receptor regulating the Wnt/β-catenin signaling resulting in hepatocellular carcinoma by inhibiting the phosphorylation activity of GSK-3β.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), the most common primary liver cancer, remains a major global health burden due to its aggressive metastatic behavior and poor prognosis. Clarification of the molecular basis underlying metastasis and recurrence is essential for advancing therapeutic development. The present study examines the contribution of hyaluronan-mediated motility receptor (HMMR) to HCC progression and its clinical implications.
methodsEighty paired HCC tumor and adjacent non-tumor tissues were obtained from patients who underwent radical resection. HMMR expression was evaluated by immunohistochemistry, Western blotting, and quantitative real-time PCR (qPCR). Kaplan-Meier and Cox regression analyses were employed to determine the association of HMMR expression with overall survival (OS) and recurrence-free survival (RFS). Functional assays were performed in Huh7 and Hep3B cells with HMMR knockdown or overexpression, including CCK-8 assays for proliferation, Transwell assays for migration and invasion, and Western blotting/qPCR for assessing epithelial-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin, vimentin) and Wnt/β-catenin signaling components (GSK-3β, β-catenin, cyclin D1, c-myc). A subcutaneous xenograft model in nude mice was established to evaluate the effect of HMMR on tumor growth in vivo. Gene set variation analysis (GSVA) and molecular docking were applied to investigate HMMR-related pathways and potential protein-protein interactions.
resultsHMMR expression was markedly elevated in HCC tissues compared with adjacent tissues (p < 0.001) at both mRNA and protein levels. Patients with high HMMR expression exhibited reduced median OS (27.8 vs. 32.3 months, p = 0.012) and RFS (9.6 vs. 12.6 months, p = 0.017). In vitro experiments demonstrated that HMMR silencing suppressed Huh7/Hep3B cell proliferation, migration (p < 0.01), and invasion (p < 0.001), while increasing E-cadherin and GSK-3β expression and reducing N-cadherin, vimentin, β-catenin, cyclin D1, and c-myc. Conversely, HMMR overexpression produced opposite effects. In xenograft models, tumors with HMMR knockdown displayed slower growth. GSVA indicated a positive correlation of HMMR expression with EMT and Wnt/β-catenin signaling, and molecular docking confirmed the binding capacity of HMMR to GSK-3β and β-catenin. Mechanistic analysis showed that HMMR suppressed GSK-3β phosphorylation activity, limiting β-catenin ubiquitination and degradation, thereby activating Wnt/β-catenin signaling and driving EMT.
conclusionsHMMR stabilizes β-catenin by suppressing GSK-3β phosphorylation activity, which reduces β-catenin ubiquitination and degradation. Knocking down HMMR enhances GSK-3β expression and its degradative effect on β-catenin, thereby lowering β-catenin protein levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.